JP2023543858A - 酸－塩基中和合剤を含む医薬組成物及びその使用 - Google Patents

酸－塩基中和合剤を含む医薬組成物及びその使用 Download PDF

Info

Publication number
JP2023543858A
JP2023543858A JP2023519733A JP2023519733A JP2023543858A JP 2023543858 A JP2023543858 A JP 2023543858A JP 2023519733 A JP2023519733 A JP 2023519733A JP 2023519733 A JP2023519733 A JP 2023519733A JP 2023543858 A JP2023543858 A JP 2023543858A
Authority
JP
Japan
Prior art keywords
acid
agent
pharmaceutical composition
weak
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023519733A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023543858A5 (enExample
Inventor
ゾウ，ファンリン
ゾウ，リーチャン
ワン，ジェンシャ
Original Assignee
チェンドゥ クァチャンアオプー メディカル テクノロジー カンパニー リミテッド
クァチャン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202011064448.1A external-priority patent/CN114306392A/zh
Priority claimed from CN202011059746.1A external-priority patent/CN114306612A/zh
Priority claimed from PCT/CN2021/076749 external-priority patent/WO2021164706A1/zh
Application filed by チェンドゥ クァチャンアオプー メディカル テクノロジー カンパニー リミテッド, クァチャン インコーポレイテッド filed Critical チェンドゥ クァチャンアオプー メディカル テクノロジー カンパニー リミテッド
Publication of JP2023543858A publication Critical patent/JP2023543858A/ja
Publication of JP2023543858A5 publication Critical patent/JP2023543858A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
JP2023519733A 2020-09-30 2021-09-30 酸－塩基中和合剤を含む医薬組成物及びその使用 Pending JP2023543858A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
CN202011064448.1A CN114306392A (zh) 2020-09-30 2020-09-30 益生菌组分的应用以及包含益生菌组分的药物组合物
CN202011064448.1 2020-09-30
CN202011059746.1 2020-09-30
CN202011059746.1A CN114306612A (zh) 2020-09-30 2020-09-30 非致病性细胞相关组分的应用以及包含非致病性细胞相关组分的药物组合物
CNPCT/CN2021/076749 2021-02-18
PCT/CN2021/076749 WO2021164706A1 (zh) 2020-02-18 2021-02-18 包含亚甲蓝类染料的药物组合物及其应用
CNPCT/CN2021/077290 2021-02-22
CN2021077290 2021-02-22
CNPCT/CN2021/078914 2021-03-03
CN2021078914 2021-03-03
PCT/CN2021/122041 WO2022068918A1 (zh) 2020-09-30 2021-09-30 包含酸碱中和组合的药物组合物及其应用

Publications (2)

Publication Number Publication Date
JP2023543858A true JP2023543858A (ja) 2023-10-18
JP2023543858A5 JP2023543858A5 (enExample) 2024-10-08

Family

ID=80951243

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023519733A Pending JP2023543858A (ja) 2020-09-30 2021-09-30 酸－塩基中和合剤を含む医薬組成物及びその使用

Country Status (4)

Country Link
US (1) US20230414617A1 (enExample)
EP (1) EP4223313A4 (enExample)
JP (1) JP2023543858A (enExample)
WO (1) WO2022068918A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023050297A1 (zh) * 2021-09-30 2023-04-06 成都夸常奥普医疗科技有限公司 一种局部药物组合物、应用及试剂盒
WO2023051682A1 (zh) * 2021-09-29 2023-04-06 成都夸常奥普医疗科技有限公司 一种局部药物组合物、应用及试剂盒
WO2026119290A1 (zh) * 2024-12-05 2026-06-11 成都夸常奥普医疗科技有限公司 局部药剂的新用途、新治疗方法、相关制剂、和试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020043185A1 (zh) * 2018-08-31 2020-03-05 成都夸常奥普医疗科技有限公司 氨基酸类营养素的应用以及包含它的药物组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1090942C (zh) * 1994-05-20 2002-09-18 郑继刚 一种用于治疗囊性肿瘤和血管瘤的复方磷酸液
WO2016070032A1 (en) * 2014-10-30 2016-05-06 Neurotronic, Inc. Chemical ablation and method of treatment for various diseases
CN108686216A (zh) * 2017-04-07 2018-10-23 成都夸常科技有限公司 包含化学消融剂和生物活性多糖的药物组合物及其用途
CN108685926A (zh) * 2017-04-07 2018-10-23 成都夸常科技有限公司 包含化学消融剂和生物活性苷的药物组合物及其用途
CN110870869A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 包含糖类营养素和常规无效化合物的药物组合物及其应用
CN110870868A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 包含亚甲蓝类染料、营养素或/和抗肿瘤化合物的药物组合物及其应用
CN110870858A (zh) * 2018-08-31 2020-03-10 成都夸常奥普医疗科技有限公司 包含有机酸酸化剂和常规无效化合物的药物组合物及其应用
CN112439066A (zh) * 2019-08-30 2021-03-05 成都夸常奥普医疗科技有限公司 包含化学消融剂和pH调节剂的药物组合物及其应用
CN112438942A (zh) * 2019-08-30 2021-03-05 成都夸常奥普医疗科技有限公司 包含碱化剂及其协同物的药物组合物及其应用
WO2021164706A1 (zh) * 2020-02-18 2021-08-26 成都夸常奥普医疗科技有限公司 包含亚甲蓝类染料的药物组合物及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020043185A1 (zh) * 2018-08-31 2020-03-05 成都夸常奥普医疗科技有限公司 氨基酸类营养素的应用以及包含它的药物组合物

Also Published As

Publication number Publication date
WO2022068918A1 (zh) 2022-04-07
EP4223313A4 (en) 2024-11-13
EP4223313A1 (en) 2023-08-09
US20230414617A1 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
JP7568185B2 (ja) アミノ酸ベースの栄養素の使用及びそれを含む医薬組成物
US10500219B2 (en) Compositions and methods for tissue regeneration
US12171747B2 (en) Material and method for treating cancer
US20230414617A1 (en) Pharmaceutical composition comprising acid-base neutralization combination and application thereof
CN110870868A (zh) 包含亚甲蓝类染料、营养素或/和抗肿瘤化合物的药物组合物及其应用
CN110870869A (zh) 包含糖类营养素和常规无效化合物的药物组合物及其应用
WO2021164706A1 (zh) 包含亚甲蓝类染料的药物组合物及其应用
JP2023544310A (ja) プロバイオティクス成分の使用及びプロバイオティクス成分を含む医薬組成物
US20210128548A1 (en) External preparation comprising pyridonecarboxylic acid derivative
CN110870858A (zh) 包含有机酸酸化剂和常规无效化合物的药物组合物及其应用
KR101245960B1 (ko) 피리돈카르복시산 유도체를 함유하는 로션제
BR112021002156A2 (pt) tratamento de verrugas
CN112438942A (zh) 包含碱化剂及其协同物的药物组合物及其应用
CN110870860A (zh) 包含氨基酸类营养素和常规无效化合物的药物组合物及其应用
WO2021163897A1 (zh) 包含亚甲蓝类染料、营养素或/和常规抗肿瘤药的药物组合物及其应用
CN112439066A (zh) 包含化学消融剂和pH调节剂的药物组合物及其应用
HK40098697A (en) Pharmaceutical composition comprising acid-base neutralization combination and application thereof
US11147785B2 (en) Modified free amino acid formulation and uses
WO2022174812A1 (zh) 包含免疫球蛋白的药物组合物及其应用
HK40098696A (en) Use of probiotic component and pharmaceutical composition containing probiotic component
HK40042096A (en) Use of amino acid based nutrients and pharmaceutical composition containing the same
EA002267B1 (ru) Ранозаживляющий, противовоспалительный и противоинфекционный лекарственный препарат
TW202535906A (zh) 新型短鏈肽及其衍生物
JP2026007336A (ja) 活性酸素消去剤
CN113230420A (zh) 包含亚甲蓝类活体染料的水基乳剂、该乳剂的应用以及包含该乳剂的药物组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240930

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251118

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260519